163 related articles for article (PubMed ID: 34432979)
1. Optimization of a Series of RIPK2 PROTACs.
Miah AH; Smith IED; Rackham M; Mares A; Thawani AR; Nagilla R; Haile PA; Votta BJ; Gordon LJ; Watt G; Denyer J; Fisher DT; Dace P; Giffen P; Goncalves A; Churcher I; Scott-Stevens P; Harling JD
J Med Chem; 2021 Sep; 64(17):12978-13003. PubMed ID: 34432979
[TBL] [Abstract][Full Text] [Related]
2. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.
Mares A; Miah AH; Smith IED; Rackham M; Thawani AR; Cryan J; Haile PA; Votta BJ; Beal AM; Capriotti C; Reilly MA; Fisher DT; Zinn N; Bantscheff M; MacDonald TT; Vossenkamper A; Dace P; Churcher I; Benowitz AB; Watt G; Denyer J; Scott-Stevens P; Harling JD
Commun Biol; 2020 Mar; 3(1):140. PubMed ID: 32198438
[TBL] [Abstract][Full Text] [Related]
3. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
Ermann J; Matmusaev M; Haley EK; Braun C; Jost F; Mayer-Wrangowski S; Hsiao P; Ting N; Li L; Terenzio D; Chime J; Lukas S; Patnaude L; Panzenbeck M; Csordas D; Zheng J; Mierz D; Simpson T; King FJ; Klimowicz AP; Mbow ML; Fine JS; Miller CA; Fogal SE; Byrne FR
Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G500-G512. PubMed ID: 34494462
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
Yuan X; Chen Y; Tang M; Wei Y; Shi M; Yang Y; Zhou Y; Yang T; Liu J; Liu K; Deng D; Zhang C; Chen L
J Med Chem; 2022 Jul; 65(13):9312-9327. PubMed ID: 35709396
[TBL] [Abstract][Full Text] [Related]
5. Cell death gene expression profile: role of RIPK2 in dengue virus-mediated apoptosis.
Morchang A; Yasamut U; Netsawang J; Noisakran S; Wongwiwat W; Songprakhon P; Srisawat C; Puttikhunt C; Kasinrerk W; Malasit P; Yenchitsomanus PT; Limjindaporn T
Virus Res; 2011 Mar; 156(1-2):25-34. PubMed ID: 21195733
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.
Fan T; Ji Y; Chen D; Peng X; Ai J; Xiong B
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):282-293. PubMed ID: 36408835
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of receptor-interacting serine/threonine protein kinase-2 (RIPK2) affects EMT-associated gene expression in human hepatoma cells.
Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
Anticancer Res; 2012 Sep; 32(9):3775-83. PubMed ID: 22993319
[TBL] [Abstract][Full Text] [Related]
8. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.
Suebsuwong C; Pinkas DM; Ray SS; Bufton JC; Dai B; Bullock AN; Degterev A; Cuny GD
Bioorg Med Chem Lett; 2018 Feb; 28(4):577-583. PubMed ID: 29409752
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2.
Wagner RN; Reed JC; Chanda SK
Retrovirology; 2015 Aug; 12():74. PubMed ID: 26297639
[TBL] [Abstract][Full Text] [Related]
10. RIPK2 NODs to XIAP and IBD.
Topal Y; Gyrd-Hansen M
Semin Cell Dev Biol; 2021 Jan; 109():144-150. PubMed ID: 32631784
[TBL] [Abstract][Full Text] [Related]
11. A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours.
Zhang H; Ma Y; Zhang Q; Liu R; Luo H; Wang X
BMC Med Genomics; 2022 Apr; 15(1):97. PubMed ID: 35473583
[TBL] [Abstract][Full Text] [Related]
12. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
13. Pathogen-mediated proteolysis of the cell death regulator RIPK1 and the host defense modulator RIPK2 in human aortic endothelial cells.
Madrigal AG; Barth K; Papadopoulos G; Genco CA
PLoS Pathog; 2012; 8(6):e1002723. PubMed ID: 22685397
[TBL] [Abstract][Full Text] [Related]
14. RIPK2 as a promising druggable target for autoimmune diseases.
Zhao W; Leng RX; Ye DQ
Int Immunopharmacol; 2023 May; 118():110128. PubMed ID: 37023697
[TBL] [Abstract][Full Text] [Related]
15. Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice.
Cavallari JF; Barra NG; Foley KP; Lee A; Duggan BM; Henriksbo BD; Anhê FF; Ashkar AA; Schertzer JD
Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E579-E585. PubMed ID: 32101030
[TBL] [Abstract][Full Text] [Related]
16. Activation of NOD2/RIPK2 pathway induces mitochondrial injury to oligodendrocyte precursor cells in vitro and CNS demyelination in vivo.
Natarajan C; Yao SY; Zhang F; Sriram S
J Neuroimmunol; 2013 Dec; 265(1-2):51-60. PubMed ID: 24169446
[TBL] [Abstract][Full Text] [Related]
17. XIAP controls RIPK2 signaling by preventing its deposition in speck-like structures.
Ellwanger K; Briese S; Arnold C; Kienes I; Heim V; Nachbur U; Kufer TA
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31350258
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression.
Wu S; Kanda T; Imazeki F; Nakamoto S; Tanaka T; Arai M; Roger T; Shirasawa H; Nomura F; Yokosuka O
J Infect Dis; 2012 Aug; 206(3):415-20. PubMed ID: 22615316
[TBL] [Abstract][Full Text] [Related]
19. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
